Research led by Brock University has found a possible cure for lung diseases typically found in older adults, such as pulmonary fibrosis. The findings are published in the journal Aging Cell.

For patients with COPD, budesonide-glycopyrrolate-formoterol does not improve clinical outcomes compared with fluticasone-umeclidinium-vilanterol.

In a cohort of adults with chronic obstructive pulmonary disease (COPD), receiving fluticasone-umeclidinium-vilanterol was ...

A study compares budesonide-glycopyrrolate-formoterol and fluticasone-umeclidinium-vilanterol, revealing insights on COPD ...

Metered-dose inhaler budesonide-glycopyrrolate-formoterol (Breztri Aerosphere) was associated with a higher risk of a first ...

The top two FDA pulmonology stories from this year focused on the approval of a once-daily tablet that includes ... for adults with pulmonary arterial hypertension (PAH) and the approval of ...

With the entire NBA having off on Wednesday and only the Bucks and Thunder playing on Tuesday as Milwaukee won the 2024 NBA Cup, Thursday is filled with options for daily Fantasy basketball ...

COPD and asthma devices are crucial in the management and treatment of respiratory diseases, providing relief and improving the quality of life for patients. These devices range from inhalers to ...

All LABAs are associated with an increased risk of asthma-related deaths. Indacaterol is indicated for patients with COPD and not for patients with asthma. Indacaterol should not be used for ...